The Effect of Pituitary Gland Disorders on Glucose Metabolism: From Pathophysiology to Management

Abstract

This review aims to explore, present, and discuss disorders of glucose metabolism implicated in pituitary gland diseases, the appropriate interventions, as well as the therapeutic challenges that may arise. Pituitary pathologies may dysregulate glucose homeostasis, as both the excess and deficiency of various pituitary hormones can affect glucose metabolism. Increased circulating levels of growth hormone, glucocorticoids or prolactin have been shown to mainly provoke hyperglycemic states, while hypopituitarism can be associated with both hyperglycemia and hypoglycemia. Addressing the primary cause of these disorders with the use of surgery, medical treatment or radiotherapy forms the cornerstone of current management strategies. Physicians should bear in mind that some such medications have an unfavorable effect on glucose metabolism too. When unsuccessful, or until the appropriate treatment of the underlying pituitary problem, the addition of established antidiabetic therapies might prove useful. Further studies aiming to discover more accurate and effective drug preparations in combination with optimal lifestyle management models will contribute to achieving a more successful glycemic control in these patients.

Key words

acromegaly - hyperprolactinemia - hypoglycemia - hyperglycemia - pituitary - type 2 diabetes

Publication History

Received: 24 July 2020

Accepted after revision: 02 September 2020

Article published online:
12 October 2020

• References

• 1 Dal J, List EO, Jorgensen JOL. et al. Glucose and fat metabolism in acromegaly: from mice models to patient care. Neuroendocrinology 2016; 103: 96-105
• 2 Schernthaner G, Prager R, Punzengruber C. et al. Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985; 28: 138-142
• 3 Dogan BA, Berker D, Arduc A. et al. Insulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinoma. Minerva Endocrinol 2016; 41: 175-182
• 4 Geer EB, Shen W, Strohmayer E. et al. Body composition and cardiovascular risk markers after remission of Cushing’s Disease: A prospective study using whole-body MRI. J Clin Endocrinol Metab 2012; 97: 1702-1711
• 5 Munir A, Newell-Price J. Management of diabetes mellitus in cushing’s syndrome. Neuroendocrinology 2010; 92: 82-85
• 6 Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance. Endocrinol Metab Clin North Am 2014; 43: 75-102
• 7 Gazzaruso C, Gola M, Karamouzis I. et al. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH—an update. J Clin Endocrinol Metab 2014; 99: 18-29
• 8 Barkan AL, Burman P, Clemmons DR. et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005; 90: 5684-5691
• 9 Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2008; 37: 101-122
• 10 Chen Y, Sun D, Krishnamurthy VMR. et al. Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2/STAT5 signal transduction and STAT5b DNA binding. Am J Physiol Metab 2007; 292: E1856-E1862
• 11 Paschou SA, Kanaka-Gantenbein C, Chrousos GP. et al. Growth hormone axis in patients with chronic kidney disease. Hormones 2019; 18: 71-73
• 12 Clemmons DR. Metabolic actions of insulin-like growth factor-i in normal physiology and diabetes. Endocrinol Metab Clin North Am 2012; 41: 425-443
• 13 Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes 2001; 50: S140-S145
• 14 Colao A, Auriemma RS, Galdiero M. et al. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 2009; 94: 528-537
• 15 Ronchi CL, Varca V, Beck-Peccoz P. et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006; 91: 121-128
• 16 Colao A, Auriemma RS, Savastano S. et al. Glucose tolerance and somatostatin analog treatment in acromegaly: A 12-Month Study. J Clin Endocrinol Metab 2009; 94: 2907-2914
• 17 Baldelli R, Battista C, Leonetti F. et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003; 59: 492-499
• 18 McKeage K. Pasireotide in acromegaly: a review. Drugs 2015; 75: 1039-1048
• 19 Henry RR, Ciaraldi TP, Armstrong D. et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013; 98: 3446-3453
• 20 Ghigo E, Biller BMK, Colao A. et al. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. J Endocrinol Invest 2009; 32: 924-933
• 21 Bajetta E, Procopio G, Catena L. et al. Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors. Cancer 2006; 107: 2474-2481
• 22 Singh V, Brendel MD, Zacharias S. et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: An in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007; 92: 673-680
• 23 Bruns C, Lewis I, Briner U. et al. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 707-716
• 24 Atiya A. Intraislet somatostatin inhibits insulin (via a subtype-2 somatostatin receptor) but not islet amyloid polypeptide secretion in the isolated perfused human pancreas. J Gastrointest Surg 1997; 1: 251-256
• 25 Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 2012; 212: 49-60
• 26 Ludvigsen E, Stridsberg M, Taylor JE. et al. Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Regul Pept 2007; 138: 1-9
• 27 Tzanela M, Vassiliadi DA, Gavalas N. et al. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol (Oxf) 2011; 75: 96-102
• 28 Baroni MG, Giorgino F, Pezzino V. et al. Italian Society for the study of diabetes (SID)/italian endocrinological society (SIE) guidelines on the treatment of hyperglycemia in cushing’s syndrome and acromegaly. J Endocrinol Invest 2016; 39: 235-255
• 29 Auriemma RS, De Alcubierre D, Pirchio R. et al. Glucose abnormalities associated to prolactin secreting pituitary adenomas. Front Endocrinol (Lausanne) 2019; 10: 327
• 30 Nilsson L, Binart N, Bohlooly-Y M. et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 2005; 331: 1120-1126
• 31 Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes, Obes Metab 2007; 9: 464-476
• 32 Ling C, Svensson L, Oden B. et al. Identification of functional prolactin (PRL) receptor gene expression: prl inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 2003; 88: 1804-1808
• 33 Hogan JC, Stephens JM. The regulation of fatty acid synthase by STAT5A. Diabetes 2005; 54: 1968-1975
• 34 Combs TP, Berg AH, Rajala MW. et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003; 52: 268-276
• 35 Weinhaus AJ, Stout LE, Bhagroo NV. et al. Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol 2007; 193: 367-381
• 36 Sorenson R, Brelje T. Adaptation of islets of langerhans to pregnancy: b-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 1997; 29: 301-307
• 37 Labriola L, Montor WR, Krogh K. et al. Beneficial effects of prolactin and laminin on human pancreatic islet-cell cultures. Mol Cell Endocrinol 2007; 263: 120-133
• 38 Fleenor DE, Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5*. Endocrinology 2001; 142: 2805-2810
• 39 Cejkova P, Fojtikova M, Cerna M. Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 2009; 9: 23-27
• 40 Landgraf R, Landgraf-Leurs MMC, Weissmann A. et al. Prolactin: a diabetogenic hormone. Diabetologia 1977; 13: 99-104
• 41 Tuzcu A, Yalaki S, Arikan S. et al. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 2009; 12: 330-334
• 42 Park S, Kim DS, Daily JW. et al. Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev 2011; 27: 564-574
• 43 Park S, Kang S, Lee H-W. et al. Central prolactin modulates insulin sensitivity and insulin secretion in diabetic rats. Neuroendocrinology 2012; 95: 332-343
• 44 Doknic M, Pekic S, Zarkovic M. et al. Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 77-84
• 45 Lyons DJ, Hellysaz A, Broberger C. Prolactin regulates tuberoinfundibular dopamine neuron discharge pattern: novel feedback control mechanisms in the lactotrophic axis. J Neurosci 2012; 32: 8074-8083
• 46 Berinder K, Nystrom T, Hoybye C. et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 199-207
• 47 DeFronzo RA. Bromocriptine: A Sympatholytic, D2-Dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011; 34: 789-794
• 48 Cincotta AH. Hypothalamic role in the insulin resistance syndrome In: insulin resistance syndrome. Hansen B, Shaffrir E, eds London: Taylor and Francis; 2002
• 49 Cincotta AH, Meier AH, Cincotta M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8: 1683-1707
• 50 Pijl H, Ohashi S, Matsuda M. et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-1161
• 51 Gaziano JM, Cincotta AH, OConnor CM. et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33: 1503-1508
• 52 Pala NA, Laway BA, Misgar RA. et al. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr 2015; 7: 99
• 53 Ruiz-Herrera X, de los Rios EA, Diosaz JM. et al. Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males. Endocrinology 2016; 2016-1444
• 54 Wagner R, Heni M, Linder K. et al. Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol 2014; 51: 71-78
• 55 Balbach L, Wallaschofski H, Volzke H. et al. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?. BMC Endocr Disord 2013; 13: 12
• 56 Li J, Rice MS, Huang T. et al. Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia 2018; 61: 2549-2560
• 57 Fasshauer M, Klein J, Neumann S. et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089
• 58 Feelders RA, Pulgar SJ, Kempel A. et al. Management of endocrine disease: the burden of cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012; 167: 311-326
• 59 Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011; 22: 499-506
• 60 Mazziotti G, Formenti AM, Frara S. et al. Diabetes in cushing disease. Curr Diab Rep 2017; 17: 32
• 61 Scaroni C, Zilio M, Foti M. et al. Glucose metabolism abnormalities in cushing syndrome: from molecular basis to clinical management. Endocr Rev 2017; 38: 189-219
• 62 Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24: 28-47
• 63 Colao A, Petersenn S, Newell-Price J. et al. A 12-month phase 3 study of pasireotide in Cushing’s Disease. N Engl J Med 2012; 366: 914-924
• 64 MacKenzie Feder J, Bourdeau I, Vallette S. et al. Pasireotide monotherapy in cushing’s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary 2014; 17: 519-529
• 65 Boscaro M, Bertherat J, Findling J. et al. Extended treatment of cushing’s disease with pasireotide: results from a 2-year, phase II study. Pituitary 2014; 17: 320-326
• 66 Davies MJ, DAlessio DA, Fradkin J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetes Care 2018; 41: 2669-2701
• 67 Ferrau F, Korbonits M. Metabolic comorbidities in cushing’s syndrome. Eur J Endocrinol 2015; 173: M133-M157
• 68 Upadhyay J, Polyzos SA, Perakakis N. et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism 2018; 78: 13-42
• 69 Ambrosi B, DallAsta C, Cannavo S. et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in cushing’s disease. Eur J Endocrinol 2004; 173-178
• 70 Cannavo S, Ambrosi B, Chiodini I. et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in cushing’s disease. J Endocrinol Invest 2004; 27: RC8-RC11
• 71 Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in cushing’s disease. J Clin Endocrinol Metab 2005; 90: 1340-1346
• 72 Nauck M, Stockmann F, Ebert R. et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52
• 73 van Raalte DH, van Genugten RE, Linssen MML. et al. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced Glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011; 34: 412-417
• 74 Conrado DJ, Krishnaswami S, Shoji S. et al. Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis. J Pharmacokinet Pharmacodyn 2016; 43: 325-341
• 75 Anderson A, Walker BR. 11b-HSD1 Inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs 2013; 73: 1385-1393
• 76 Lee NK, Sowa H, Hinoi E. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-469
• 77 Ioakim KJ, Sydney GI, Paschou SA. Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management. Hormones 2020; 19: 135-143
• 78 Hwang Y-C, Jeong I-K, Ahn KJ. et al. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced b-cell function in middle-aged male subjects. Diabetes Metab Res Rev 2009; 25: 768-772
• 79 Winhofer Y, Handisurya A, Tura A. et al. Osteocalcin is related to enhanced insulin secretion in gestational diabetes mellitus. Diabetes Care 2010; 33: 139-143
• 80 Herrmann BL, Saller B, Stratmann M. et al. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome. Horm Metab Res 2005; 37: 49-52
• 81 Twickler TB, Cramer MJM, Dallinga-Thie GM. et al. Adult-onset growth hormone deficiency: relation of postprandial dyslipidemia to premature atherosclerosis. J Clin Endocrinol Metab 2003; 88: 2479-2488
• 82 Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 2004; 113: 25-27
• 83 Liu J-L, Coschigano KT, Robertson K. et al. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. Am J Physiol Metab 2004; 287: E405-E413
• 84 Guo Y, Lu Y, Houle D. et al. Pancreatic islet-specific expression of an insulin-like growth factor-i transgene compensates islet cell growth in growth hormone receptor gene-deficient mice. Endocrinology 2005; 146: 2602-2609
• 85 Gola M, Bonadonna S, Doga M. et al. Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 2005; 90: 1864-1870
• 86 Miller KK, Biller BMK, Lipman JG. et al. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab 2005; 90: 768-774
• 87 Yuen KCJ, Frystyk J, White DK. et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 2005; 63: 428-436
• 88 Kim SY. Diagnosis and treatment of hypopituitarism. Endocrinol Metab 2015; 30: 443
• 89 Paschou SA, Vryonidou A, Goulis DG. Pituitary incidentalomas: a guide to assessment, treatment and follow-up. Maturitas 2016; 92: 143-149